Cost-effectiveness analysis of aducanumab versus placebo for patients with mild cognitive impairment and mild Alzheimer’s disease
Even with the updated price being half of the original, aducanumab is still not cost-effective, underscoring the need for affordable, evidence-based AD treatments.
Authors
- James King (ORCID: https://orcid.org/0000-0001-9969-9541)
- Xiaomo Xiong (ORCID: https://orcid.org/0000-0001-5657-5733)
- Kevin Lu (ORCID: https://orcid.org/0000-0002-6380-0836)
- Jing Yuan (ORCID: https://orcid.org/0000-0003-0906-1822)
- Gang Lv
- Minghui Li (ORCID: https://orcid.org/0000-0003-1909-6260)
Institutions
- University of South Carolina (US)
- University of Tennessee Health Science Center (US)
- University of Macau (MO)
- Chinese PLA General Hospital (CN)
- University of Cincinnati Medical Center (US)
Publication Details
- Journal
- BMJ Open
- Published
- 2025-04-01
- DOI
- https://doi.org/10.1136/bmjopen-2024-090403
- Citations
- 4
- Primary Topic
- Health Systems, Economic Evaluations, Quality of Life
- Type
- article
- Field-Weighted Citation Impact
- 12.52
Funders
- Alzheimer's Association